Mira Pharmaceuticals completes Phase 1 dosing of Ketamir-2

MIRA Pharmaceuticals (MIRA) announced completion of dosing in its Phase 1 clinical trial evaluating Ketamir-2, the Company’s proprietary selective oral NMDA receptor modulator. The randomized, double-blind, placebo-controlled study enrolled 56 healthy adult volunteers across single ascending dose and multiple ascending dose cohorts. Based on safety data reviewed to date, no serious adverse events or dose-limiting toxicities have been reported at any dose level tested. In addition, no clinically significant dissociative or psychotomimetic effects typically associated with ketamine were observed. Database lock, unblinding, and final audited pharmacokinetic and safety analyses are underway. Phase 1 data have been accepted for presentation at the upcoming American Association for Cancer Research Annual Meeting.